Allergy Diagnostics is anticipated to have CAGR of ~x% over 2019-2028. The allergy diagnosis is an important preliminary step for effective allergy treatment. The recent advanced allergy tests are more convenient and accurate compared to the tests that were available before. The growth is attributed to the rise in the incidences of allergic conditions which would lead to a lucrative growth during the forecast period. The increase in the access to the medical insurances is anticipated to flourish the industry in the coming years. The large economic burden of the allergic diseases would help the industry to boost in the coming years.

Top Driver: Increase in the incidences of the allergic reaction to boost the industry

Allergy Diagnostics is projected to grow with the surge in incidences of the allergic reactions in the coming years. According to the Asthma and Allergy Foundation of America, more than 50 million Americans have experienced various types of allergies each year. Furthermore, according to the estimates given, allergies are the 6th leading cause of chronic illness in the U.S. Allergic conditions are the most common health issues affecting children in the U.S. In 2015, 8.2 percent of adults and 8.4 percent of children were diagnosed with hay fever. The growth in this number is attributed to help the industry gain a lucrative pace in the near future.

Inhaled Allergen to Make Crucial Contribution to Growth of Global Allergy Diagnostics Market

Among allergen type segments of the global Allergy Diagnostics market, inhaled allergens segment is anticipated to grow in the forecast period. This owes to the surge in the incidences of respiratory allergies and asthma across the countries is anticipated to boost in the forecast period. The surge in the number of industries causing pollution is expected to affect the majority of the population causing respiratory disorders, which would help the market to flourish. The drug allergens segment is estimated to experience highest CAGR due to the difference in the body mechanisms and hence the response which may lead to the allergic reaction and hence would propel the market growth in the coming years.

  Surge In The Incidences Of Respiratory Allergic Disorders To Benefit North America Market

North America is experiencing highest revenue growth than any other country and is anticipated to boost further in the coming years. This owes to the rise in incidence of respiratory allergic disorders coupled with the surge in awareness levels regarding allergy diagnostics is expected to flourish in the coming years. The adoption of in vitro blood tests would contribute to the growth. The growing geriatric population and rising incidences of allergic conditions are also contributing to the region’s growth. Asia Pacific is expected to show highest CAGR in the regional market registering a due to rapidly improvising healthcare infrastructure, unmet clinical needs, and demand for minimally invasive diagnostic tools.

Due to outbreak of COVID-19 the key industries are anticipated to affect drastically in a negative downturn, due to the government enforced lockout situation. However, the surge in the awareness programs regarding the allergy diagnostics would help the industry to flourish in the current scenario.

Players to Focus on Allergy Diagnostics

The global Allergy Diagnostics market leaders include Siemens AG, Omega Diagnostics Group PLC, Hitachi Chemical Co., Ltd., bioMérieux SA, Stallergenes Greer, Thermo Fisher Scientific Inc., HOB Biotech Group Suzhou Co., Ltd., HYCOR Biomedical, Danaher Corporation,  and Lincoln Diagnostics, Inc.

Hitachi Chemical Co., Ltd.: In September 2017, Hitachi Chemical Co., Ltd. announced the conclusion of a contract with Kyowa Hakko Kirin Co., Ltd. to acquire a 66.6 percent stake in Kyowa Hakko Kirin’s wholly owned subsidiary Kyowa Medex Co., Ltd., a developer/manufacturer/supplier of in vitro diagnostics such as hyperlipidemia1 and diabetes.

Bluejay Diagnostics, Inc.: In February 2017, Bluejay Diagnostics, Inc. announced a collaborative clinical research agreement with Hitachi Chemical Co., Ltd. to develop a non-invasive, point-of-care test that measures total IgE in human tears.  The technology could be used to aid in the diagnosis of Allergic Conjunctivitis, i.e. “Pink Eye.” Under this collaboration, Hitachi Chemical will provide its technology, knowledge and understanding of the product to perform clinical trials and regulatory applications in the United States, Europe and South America.

Thermo Fisher Scientific Inc.: In March 2020, Thermo Fisher Scientific Inc., the world leader in serving science, and QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash.

Scope of the Report

By Product Type

• Assay Kits
• Consumables
• Instruments
  

By Allergen Type

• Food allergen
• Drug Allergen
• Inhales Allergen
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.